Virology News and Research

Latest Virology News and Research

NIH begins Phase 1 clinical trial of HIV vaccine candidate

GenVec announced today that the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), has begun the second Phase 1 clinical trial in healthy adult volunteers of an HIV vaccine candidate jointly developed by the Dale and Betty Bumpers Vaccine Research Center (VRC), a part of NIAID, and GenVec.

19 Jan 2005

Newly discovered virus, New Haven coronavirus

A newly discovered virus may be responsible for many respiratory tract illnesses in infants and children, and may be associated with an important multi-organ disease whose cause has remained a mystery for decades, according to articles in the Feb. 15 issue of The Journal of Infectious Diseases, now available online.

19 Jan 2005

African health leaders vow to keep polio eradication goal

Following a year in which Africa grappled with an escalating polio epidemic, ministers of health of the key affected countries today concluded that the spread of polio was slowing in most countries. They agreed to step up their vigilance and their vaccination programmes in order to meet polio eradication targets this year.

17 Jan 2005

Researchers attack cervical cancer

As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease.

17 Jan 2005

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

17 Jan 2005

MHRA and FDA to inspect Chiron's Liverpool manufacturing facility

Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.

13 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Important clue to understanding the origins of the AIDS epidemic

Medical Research Council (MRC) scientists have uncovered an important clue to understanding the origins of the AIDS epidemic. The work suggests that harnessing natural mechanisms of resistance to HIV infection might provide new methods for combating AIDS.

12 Jan 2005

Safety established for Vaxin's first flu vaccine in clinical trial

Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company's recombinant influenza vaccine provides a potential alternative to traditional flu vaccines.

12 Jan 2005

Novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some breast cancers

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

10 Jan 2005

Important clue to understanding the origins of the AIDS epidemic

10 Jan 2005

Key genetic factor determines HIV/AIDS risk

People with more copies of a gene that helps to fight HIV are less likely to become infected with the virus or to develop AIDS than those of the same geographical ancestry, such as European Americans, who have fewer copies of the gene, according to a study funded by the National Institute of Allergy and Infectious Diseases (NIAID).

10 Jan 2005

Australia attempts to develop treatments against Hendra virus and Nipah virus

With funding from the United States' National Institutes of Health (NIH), and in collaboration with a research team led by Dr Christopher Broder at the Uniformed Services University of the Health Sciences in Bethesda Maryland, CSIRO Livestock Industries' Australian Animal Health Laboratory (AAHL) in Geelong is attempting to develop treatments against Hendra virus and Nipah virus.

9 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Protein discovery with medical implications

It was a transforming moment. Researchers could barely believe their eyes. A molecular blob of a protein reshaped itself into a molecular Pacman in order to free new viruses from the inside of a bacterial cell.

6 Jan 2005

Discovery could lead to a screening test that identifies people who have a higher or lower susceptibility to HIV/AIDS

6 Jan 2005

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

DermaVir, a novel treatment for HIV/AIDS, offers a new option which complements and improves present drug therapies. The vaccine, applied topically to the skin, has demonstrated efficacy in boosting immune responses and controlling virus replication in chronically infected monkeys.

6 Jan 2005

Herpes virus is everywhere and it's unavoidable

While not the first, the researchers report that this study uses the most sensitive techniques in a cross-sectional assessment performed to date of the presence of HSV-1 DNA in the eyes and mouths of healthy individuals, in terms of population size and total samples collected.

6 Jan 2005

Virology News and Research

Latest Virology News and Research

NIH begins Phase 1 clinical trial of HIV vaccine candidate

Newly discovered virus, New Haven coronavirus

African health leaders vow to keep polio eradication goal

Researchers attack cervical cancer

Researchers have identified the cellular receptor for the JC virus

MHRA and FDA to inspect Chiron's Liverpool manufacturing facility

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Important clue to understanding the origins of the AIDS epidemic

Safety established for Vaxin's first flu vaccine in clinical trial

Novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some breast cancers

Important clue to understanding the origins of the AIDS epidemic

Key genetic factor determines HIV/AIDS risk

Australia attempts to develop treatments against Hendra virus and Nipah virus

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Protein discovery with medical implications

Discovery could lead to a screening test that identifies people who have a higher or lower susceptibility to HIV/AIDS

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

Herpes virus is everywhere and it's unavoidable

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey